Biotechnology firms are increasingly considering conducting early-phase trials outside the U.S. due to the FDA’s evolving approach to AI, exemplified by the introduction of its AI tool Elsa, which raises concerns about reliability, transparency, and the implications for regulatory processes and decision-making in the sector.
View full story…
FDA’s AI Tool Elsa Signals Shift in Biotechnology Regulation
